Media coverage about Bio-Rad Laboratories (NYSE:BIO) has been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bio-Rad Laboratories earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 46.0901136459044 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the news stories that may have impacted Accern’s rankings:

Several research analysts have commented on the company. Zacks Investment Research raised Bio-Rad Laboratories from a “hold” rating to a “strong-buy” rating and set a $291.00 target price on the stock in a report on Wednesday, December 13th. Wells Fargo & Co reissued an “outperform” rating and issued a $290.00 price objective (up from $250.00) on shares of Bio-Rad Laboratories in a research note on Wednesday, November 29th. TheStreet raised Bio-Rad Laboratories from a “c+” rating to a “b-” rating in a research note on Monday, November 13th. Finally, Deutsche Bank reissued a “buy” rating and issued a $255.00 price objective on shares of Bio-Rad Laboratories in a research note on Monday, September 18th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $277.75.

Shares of Bio-Rad Laboratories (NYSE:BIO) traded down $2.84 during trading hours on Friday, hitting $248.37. The stock had a trading volume of 176,339 shares, compared to its average volume of 184,441. The firm has a market cap of $8,610.00, a P/E ratio of 310.46, a price-to-earnings-growth ratio of 2.01 and a beta of 0.97. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.06 and a quick ratio of 2.77. Bio-Rad Laboratories has a 12 month low of $183.43 and a 12 month high of $273.87.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.54 by $0.37. The company had revenue of $535.00 million for the quarter, compared to the consensus estimate of $507.99 million. Bio-Rad Laboratories had a return on equity of 3.88% and a net margin of 5.12%. The firm’s revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.62 EPS. research analysts predict that Bio-Rad Laboratories will post 2.68 EPS for the current fiscal year.

Bio-Rad Laboratories declared that its Board of Directors has initiated a share repurchase plan on Tuesday, November 28th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the medical research company to purchase shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

In related news, EVP Michael Crowley sold 1,000 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $258.39, for a total value of $258,390.00. Following the completion of the sale, the executive vice president now directly owns 2,492 shares of the company’s stock, valued at approximately $643,907.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Christine A. Tsingos sold 4,980 shares of the business’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $249.40, for a total value of $1,242,012.00. Following the completion of the sale, the chief financial officer now directly owns 7,283 shares of the company’s stock, valued at $1,816,380.20. The disclosure for this sale can be found here. Insiders sold a total of 9,126 shares of company stock worth $2,309,426 over the last three months. 28.29% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://theolympiareport.com/2018/01/14/bio-rad-laboratories-bio-receiving-somewhat-favorable-media-coverage-analysis-finds.html.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Insider Buying and Selling by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.